| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Tempus AI, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$51.87 |
| 52 Week High | US$77.00 |
| 52 Week Low | US$22.89 |
| Beta | 0 |
| 11 Month Change | -24.24% |
| 3 Month Change | 48.20% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 28.87% |
Recent News & Updates
Shareholder Returns
| TEM | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 3.6% | -2.3% | 1.8% |
| 1Y | n/a | 10.0% | 31.9% |
Return vs Industry: Insufficient data to determine how TEM performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how TEM performed against the US Market.
Price Volatility
| TEM volatility | |
|---|---|
| TEM Average Weekly Movement | 16.5% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TEM's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine TEM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 2,000 | Eric Lefkofsky | www.tempus.com |
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies.
Tempus AI, Inc Fundamentals Summary
| TEM fundamental statistics | |
|---|---|
| Market cap | US$7.58b |
| Earnings (TTM) | -US$790.20m |
| Revenue (TTM) | US$595.57m |
13.4x
P/S Ratio-10.1x
P/E RatioIs TEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TEM income statement (TTM) | |
|---|---|
| Revenue | US$595.57m |
| Cost of Revenue | US$286.79m |
| Gross Profit | US$308.79m |
| Other Expenses | US$1.10b |
| Earnings | -US$790.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.12 |
| Gross Margin | 51.85% |
| Net Profit Margin | -132.68% |
| Debt/Equity Ratio | 450.4% |
How did TEM perform over the long term?
See historical performance and comparison